- Email: [email protected]
Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma
Abstracts S35
gy Research Group, Ninewells Hospital and Medical School, University of Dundee, Dundee, UNITED KINGDOM. RATIONALE: We evaluated the dose-response for montelukast (ML) against nasal lysine-aspirin (L-ASA) challenge in patients with aspirininduced asthma (AIA). METHODS: 12 AIA patients were randomized in double-blind crossover fashion to receive single doses of ML 10 mg (ML10), ML 40 mg (ML40), or placebo (PL), with L-ASA challenge performed 12 hours post-dosing. Measurements of peak nasal inspiratory flow (PNIF), nasal blockage visual analogue scale (VAS) and FEV1 were made over 120 minutes after L-ASA challenge. RESULTS: Pre-challenge values for mean (SEM) PNIF (l/min) were not significantly different comparing all groups; ML10: 132 (10), ML40: 125 (12) and PL: 132 (11). The maximum % PNIF fall from baseline was significantly greater (p<0.05) with PL: 45 (6) vs. ML10: 34 (6) or ML40: 32 (5). There was also a significantly greater (p<0.05) average % PNIF response over 120 minutes after L-ASA challenge for PL: 26 (7) vs. ML10: 14 (6) or ML40: 17 (6). There were no significant differences for the maximum or average % PNIF fall from baseline comparing ML10 vs. ML40. There was a significant increase (p<0.05) in VAS between baseline and 60 minutes or 120 minutes with PL, but not with ML10 or ML40. There were no significant differences for either the maximum or average % FEV1 over 120 minutes as change from baseline comparing all groups. CONCLUSION: A single dose of ML 10mg partially protected against the local effects of nasal L-ASA challenge, without further benefit at 40 mg. Nasal L-ASA challenge appeared to be a reproducible and safe method in assessing patients with AIA. Funding: University of Dundee
42
Montelukast Protects Against Nasal Lysine-Aspirin Challenge in Patients With Aspirin-Induced Asthma
K. Haggart, D. K. C. Lee, F. M. Robb, B. J. Lipworth; Asthma and Aller-
SATURDAY
J ALLERGY CLIN IMMUNOL VOLUME 113, NUMBER 2
gy Research Group, Ninewells Hospital and Medical School, University of Dundee, Dundee, UNITED KINGDOM. RATIONALE: We evaluated the dose-response for montelukast (ML) against nasal lysine-aspirin (L-ASA) challenge in patients with aspirininduced asthma (AIA). METHODS: 12 AIA patients were randomized in double-blind crossover fashion to receive single doses of ML 10 mg (ML10), ML 40 mg (ML40), or placebo (PL), with L-ASA challenge performed 12 hours post-dosing. Measurements of peak nasal inspiratory flow (PNIF), nasal blockage visual analogue scale (VAS) and FEV1 were made over 120 minutes after L-ASA challenge. RESULTS: Pre-challenge values for mean (SEM) PNIF (l/min) were not significantly different comparing all groups; ML10: 132 (10), ML40: 125 (12) and PL: 132 (11). The maximum % PNIF fall from baseline was significantly greater (p<0.05) with PL: 45 (6) vs. ML10: 34 (6) or ML40: 32 (5). There was also a significantly greater (p<0.05) average % PNIF response over 120 minutes after L-ASA challenge for PL: 26 (7) vs. ML10: 14 (6) or ML40: 17 (6). There were no significant differences for the maximum or average % PNIF fall from baseline comparing ML10 vs. ML40. There was a significant increase (p<0.05) in VAS between baseline and 60 minutes or 120 minutes with PL, but not with ML10 or ML40. There were no significant differences for either the maximum or average % FEV1 over 120 minutes as change from baseline comparing all groups. CONCLUSION: A single dose of ML 10mg partially protected against the local effects of nasal L-ASA challenge, without further benefit at 40 mg. Nasal L-ASA challenge appeared to be a reproducible and safe method in assessing patients with AIA. Funding: University of Dundee
42
Montelukast Protects Against Nasal Lysine-Aspirin Challenge in Patients With Aspirin-Induced Asthma
K. Haggart, D. K. C. Lee, F. M. Robb, B. J. Lipworth; Asthma and Aller-
SATURDAY
J ALLERGY CLIN IMMUNOL VOLUME 113, NUMBER 2